B Happl, T Balber, P Heffeter, C Denk, J M Welch, U Köster, C Alliot, A-C Bonraisin, M Brandt, F Haddad, J H Sterba, W Kandioller, M Mitterhauser, M Hacker, B K Keppler, T L Mindt
BOLD-100 (formerly IT-139, KP1339), a well-established chemotherapeutic agent, is currently being investigated in clinical trials for the treatment of gastric, pancreatic, colorectal, and bile duct cancer. Despite numerous studies, the exact mode of action is still the subject of discussions. Radiolabeled BOLD-100 could be a powerful tool to clarify pharmacokinetic pathways of the compound and to predict therapy responses in patients using nuclear molecular imaging prior to the therapy. In this study, the radiosyntheses of carrier-added (c...
March 12, 2024: Dalton Transactions: An International Journal of Inorganic Chemistry